Skip to main page content (VSports在线直播)
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site VSports app下载. .

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. V体育官网.

. 2007 May 15;109(10):4151-7.
doi: 10.1182/blood-2006-10-054528. Epub 2007 Jan 30.

Ancestry and pharmacogenetics of antileukemic drug toxicity

Shinji Kishi  1 , Cheng Cheng, Deborah French, Deqing Pei, Soma Das, Edwin H Cook, Nobuko Hijiya, Carmelo Rizzari, Gary L Rosner, Tony Frudakis, Ching-Hon Pui, William E Evans, Mary V Relling
Affiliations

Ancestry and pharmacogenetics of antileukemic drug toxicity

Shinji Kishi et al. Blood. .

Abstract

Treatment-related toxicity in acute lymphoblastic leukemia (ALL) can not only be life threatening but may also affect relapse risk. In 240 patients, we determined whether toxicities were related to 16 polymorphisms in genes linked to the pharmacodynamics of ALL chemotherapy, adjusting for age, race (self-reported or via ancestry-informative markers), sex, and disease risk group (lower- vs higher-risk therapy). Toxicities (gastrointestinal, infectious, hepatic, and neurologic) were assessed in each treatment phase. During the induction phase, when drugs subject to the steroid/cytochrome P4503A pathway predominated, genotypes in that pathway were important: vitamin D receptor (odds ratio [OR], 6. 85 [95% confidence interval [CI], 1. 73-27. 0]) and cytochrome P4503A5 (OR, 4. 61 [95% CI, 1. 11-19. 2]) polymorphisms were related to gastrointestinal toxicity and infection, respectively. During the consolidation phase, when antifolates predominated, the reduced folate carrier polymorphism predicted gastrointestinal toxicity (OR, 10. 4 [95% CI, 1. 35-80. 4]) as it also did during continuation (OR, 2. 01 [95% CI, 1 VSports手机版. 06-4. 11]). In all 3 treatment phases, a glucuronosyltransferase polymorphism predicted hyperbilirubinemia (P = . 017, P < . 001, and P < . 001) and methotrexate clearance (P = . 028), which was also independently associated with hyperbilirubinemia (P = . 026). The genotype-phenotype associations were similar whether analyses were adjusted by self-reported race or ancestry-informative genetic markers. Germ-line polymorphisms are significant determinants of toxicity of antileukemic therapy. .

PubMed Disclaimer

Figures

Figure 1
Figure 1
The interactions of antileukemic agents with gene products. Antileukemic agents (dashed boxes) interact with gene products typed in this study (genes italicized, with their functions indicated in the colored boxes). Bidirectional arrows indicate that the drugs are both substrates for and competitive inhibitors of the indicated gene products; dashed arrow indicates inductive effect of steroids on CYP3A enzymes; flat-headed arrows indicate inhibitory effects. Genotypes were determined at loci in the indicated genes and analyzed individually; they were also pooled into 1 of 3 major groups: glucocorticoid (green), phase II conjugating (blue), and antimetabolite related (red).
Figure 2
Figure 2
Concordance of self-reported and AIMs-determined race. Percentage of Sub-Saharan African, European, Native American, and East Asian ancestry as determined by AIMs (y-axes) plotted by self-reported race categories (x-axes); black, n = 44; white, n = 167; Asian, n = 1; and other, n = 28. Boxes indicate quartiles, horizontal bars indicate medians, and whiskers indicate the range after excluding outliers (circles).
Figure 3
Figure 3
Odds ratios of experiencing toxicity during therapy. Median (95% confidence intervals) odds ratios of experiencing the indicated toxicity for the 3 phases of therapy for the most predictive genotypes. Odds ratios resulting from multivariate analyses using self-declared race. The genotypes depicted were significantly associated with more than one toxicity or with toxicity in more than one phase of therapy.
Figure 4
Figure 4
Incidence of toxicity based on specific genotypes. Cumulative incidence of the first episode of grade 3 to 4 gastrointestinal (GI) toxicity differing (P = .014) by RFC genotypes during therapy (top). Cumulative incidence of the first episode of grade 3 to 4 hyperbilirubinemia differing (P < .001) by UGT1A1 genotypes, during therapy (bottom).
See this image and copyright information in PMC

References

    1. Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998;338:1663–1671. - PubMed
    1. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004;350:1535–1548. - PubMed
    1. Schrappe M, Camitta B, Pui CH, et al. Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. Leukemia. 2000;14:2193–2194. - PubMed
    1. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001;97:1211–1218. - PubMed
    1. Rivera GK, Evans WE, Kalwinsky DK, et al. Unexpectedly severe toxicity from intensive early treatment of childhood lymphoblastic leukemia. J Clin Oncol. 1985;3:201–206. - PubMed

Publication types

MeSH terms